These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27432932)

  • 21. San Antonio Breast Cancer Symposium 2016.
    Gourd K
    Lancet Oncol; 2017 Feb; 18(2):176. PubMed ID: 27989428
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjuvant therapy for all patients with breast cancer?
    Lippman ME; Hayes DF
    J Natl Cancer Inst; 2001 Jan; 93(2):80-2. PubMed ID: 11208870
    [No Abstract]   [Full Text] [Related]  

  • 23. Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer.
    Tang Y; Wang Y; Kiani MF; Wang B
    Clin Breast Cancer; 2016 Oct; 16(5):335-343. PubMed ID: 27268750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current Status of Targeted Treatment in Breast Cancer].
    Seiffert K; Schmalfeldt B; Müller V
    Dtsch Med Wochenschr; 2017 Nov; 142(22):1669-1675. PubMed ID: 29078212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.
    Janjigian YY; Braghiroli MI
    Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
    Toss A; Venturelli M; Peterle C; Piacentini F; Cascinu S; Cortesi L
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28054957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP inhibitors: targeting the right patients.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
    [No Abstract]   [Full Text] [Related]  

  • 28. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.
    Hillen U; Leiter U; Haase S; Kaufmann R; Becker J; Gutzmer R; Terheyden P; Krause-Bergmann A; Schulze HJ; Hassel J; Lahner N; Wollina U; Ziller F; Utikal J; Hafner C; Ulrich J; Machens HG; Weishaupt C; Hauschild A; Mohr P; Pföhler C; Maurer J; Wolff P; Windemuth-Kieselbach C; Schadendorf D; Livingstone E;
    Eur J Cancer; 2018 Jun; 96():34-43. PubMed ID: 29665511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab for early breast cancer.
    Thorat M
    Lancet; 2006 Jan; 367(9505):108. PubMed ID: 16413867
    [No Abstract]   [Full Text] [Related]  

  • 31. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 32. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
    Yu Q; Zhu Z; Liu Y; Zhang J; Li K
    PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
    Mayer EL
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
    [No Abstract]   [Full Text] [Related]  

  • 36. Elderly breast cancer patients: adjuvant chemotherapy and adjuvant endocrine therapy.
    Biganzoli L; Aapro M
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):137-42. PubMed ID: 15990438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.
    Liu M; Li Z; Yang J; Jiang Y; Chen Z; Ali Z; He N; Wang Z
    Cell Prolif; 2016 Aug; 49(4):409-20. PubMed ID: 27312135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 40. Beta-adrenergic signaling, a novel target for cancer therapy?
    Schuller HM
    Oncotarget; 2010 Nov; 1(7):466-469. PubMed ID: 21317444
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.